Inclusion Criteria:  Adult patients (over 18 years of age) diagnosed with severe eosinophilic asthma on benralizumab treatment for at least 4 months from the start of the study.  Exclusion Criteria:  Patients for whom no previous history is available or who do not meet the inclusion criteria.